INTRODUCTION
End-stage DIPG shows glioblastoma histology 244 and overexpression of proangiogenic factors, including VEGF 30, 244 . Whether DIPG patients benefit from anti-VEGF treatment, such as the monoclonal antibody bevacizumab, however, is still unclear 175, 219, 245 . So far, results of trials with bevacizumab have been disappointing 218, 221 . A recent drug imaging study assessing tumor uptake of zirconium-89( 89 Zr)-labeled bevacizumab in DIPG 246 showed inter and intra-patient heterogeneity, but factors determining uptake are currently unknown. 247 Therefore, this study aims to perform a 1-on-1 analysis of multiregional in vivo and ex vivo 89 Zr-bevacizumab uptake, tumor histology and vascular morphology in a DIPG patient.
MATERIALS AND METHODS
A 12-year old female patient presented with a left abducens nerve paralysis. Brain 
Immunohistochemistry
Four-μm-thick formalin-fixed, paraffin-embedded tissue sections were stained with Hematoxylin&Eosin (H&E) and immunostained as previously validated and described 
RESULTS

In vivo 89
Zr-bevacizumab Uptake
The T1 post-gadolinium-MR-images obtained eight days pre-mortem showed a 3.6x3.3cm primary pontine tumor, with strong contrast enhancement but no apparent necrosis. Furthermore, extensive meningeal and subependymal metastases in the right ventricular trigone (VTM) and cervicomedullary junction (CMM) ( Zr-bevacizumab uptake in end stage DIPG bevacizumab uptake-positivity was seen in the CMM (corr. ACmax 7800Bq/mL, SUV 9.9, volume 2.0mL), followed by the primary pontine tumor (5607Bq/mL, SUV 7.1, 13.1mL) and the VTM (2537Bq/mL, SUV 3.2, 1.2mL).
Ex vivo 89
Zr-bevacizumab Uptake Ex vivo radioactivity measurements at t=242 were performed in multiple tumor samples ( Fig. 2A) , including the VTM, primary tumor, CMM, and a small 0.02gram fragment of dural metastasis that was previously undetected by MRI and PET (Supplemental Fig.   2 ), and macroscopically normal areas of the pons, cerebellum and dura. Tracer uptake was highest in the dural metastasis (22652Bq/mL, SUV 28.7) and CMM samples, with considerable difference between the cranial (27152Bq/mL, SUV 34.4) and caudal (16184Bq/mL, SUV 20.5) part. Differences in uptake were also observed between the cranial (2949Bq/mL, SUV 3.7) and caudal (11343Bq/mL, SUV 14.4) part of the primary by Vrije Universiteit, Library on September 17, 2017. jnm.snmjournals.org Downloaded from 
Correlation Between In vivo and Ex vivo 89
Zr-bevacizumab Uptake 
Correlation Between Ex vivo 89
Zr-bevacizumab Uptake and Histology
After ex vivo radioactivity measurements, multiple samples from the primary tumor and CMM were investigated with (immuno)histochemistry to explore differences in histology as possible explanation for tracer uptake heterogeneity. H&E showed diffuse growth (Fig. 3A) . In this sample, MIB-1 staining was positive in up to 50% of tumor cells and in numerous (endothelial) cells in the microvascular walls (Fig. 3B) . In the remaining samples microvascular proliferation was less pronounced:
here, 30% (in both primary tumor samples) to 50% (in the caudal CMM sample) of tumor cell nuclei were MIB-1-positive, whereas endothelial cells were MIB-1-negative (Fig. 3B) .
GFAP was expressed in tumor cells in the primary tumor and CMM, as well as in residual non-neoplastic astrocytes (Fig. 3C) . Staining of CD34 showed partial loss of microvascular immunoreactivity in the caudal part of the primary tumor. In the other samples, CD34-immunopositivity was maintained (Fig. 3D) . Immunoreactivity for GLUT-1 was similar in all samples (Fig. 3E) . Staining of collagen-IV and SMA highlighted the vascular basal lamina and tunica media, respectively, in all samples without obvious differences (Fig.   3E ). Staining of VEGF was similar amongst all samples (Fig. 3F) .
DISCUSSION
This study directly correlates multiregional Zr-bevacizumab uptake in end stage DIPG markers. In the two samples from the pons, intra-lesional uptake heterogeneity was also observed, although here both areas showed similar vascular morphology, tumor growth, and extent of necrosis. These findings suggest that vascular proliferation is an important, yet not the only determinant of intra-lesional heterogeneity in bevacizumab uptake.
The presence of microvascular proliferation and disorganized vessels 251 in WHO grade IV glioma is considered a consequence of hypoxia-induced overexpression of proangiogenic factors, including VEGF 30, 244 . In the cranial CMM sample, glomeruloid microvascular structures with increased endothelial cell turnover (as determined by MIB-1-immunoreactivity) were prominent. Based on this, VEGF was expected to be overexpressed.
VEGF immunoreactivity, however, showed mostly aspecific staining and did not differ between samples. This may be explained by the very short half-life of the VEGF protein (15-20 minutes
252
) being incompatible with its immunohistochemical detection two hours post-mortem. Glut-1 staining was similar in all samples analyzed, suggesting a partially intact blood-brain barrier (BBB). However, our histological analysis did not provide definitive clues to determine the role of BBB integrity in bevacizumab uptake in this case.
CONCLUSION
Although concerning a single case, we conclude that in vivo PET is capable of detecting heterogeneity in bevacizumab uptake between lesions, which correlates well to ex vivo measurements. However, PET cannot detect subcentimeter intra-lesional uptake heterogeneity. Furthermore, our results suggest that targeting of bevacizumab is enhanced in areas with vascular proliferation. However, as significant inter-and intralesional heterogeneity was also observed in areas that did not show differences in vascular proliferation, other factors present in the DIPG microenvironment likely also play a role. Because the DIPG microenvironment is heterogeneous and dynamic in nature 
